Skip to main content
VIMTALABS · Health Care · 2026-08-24

Vimta Labs Ltd

5.8★ FairSolid +5.8Stage 2 · wk 4In scan: Prop Scan · Breakout WatchMARKET: WEAK RECOVERING · 2026-08-24
₹615.9
-2.19% today
₹2,752 Cr · Small cap
About this companyHealth Care· Labs & Life Sciences Services
Expand ▾

Vimta Labs Limited provides contract research and testing services in India and internationally. The company offers drug discovery, development, and drug life cycle management support services in the areas of preclinical research, clinical research, and analytical services for biopharmaceutical companies; preclinical research and testing services for medical device companies; and contract research and testing for agrochemical and specialty chemical companies. It also provides food testing and analytical development services to support manufacturers, processors, farmers, retailers, traders, exporters, and regulators; and a testing laboratory for water, alcoholic, and non-alcoholic beverages. In addition, the company offers environmental regulatory services, such as impact assessments and post project monitoring, to various industries, including power, infrastructure, cement, oil and gas, and mining, etc.; and EMI/EMC testing for electronic and electrical products/components. It provides solutions to agriculture, biologics and biosimilars, home and personal care, medical device, specialty chemicals, food, electrical and electronics, nutraceuticals, water and beverages, pharmaceuticals, crop care, environment, health and safety, and packaging industries. Vimta Labs Limited was founded in 1984 and is headquartered in Hyderabad, India.

Visit company website →
P/E (TTM)
26.6
Forward —
Earnings Growth (YoY)
+18.2%
Revenue +14.0%
ROE
+18.6%
Profit margin +19.0%
Dividend Yield
0.43%
P/B 4.9
vs 52W High
-29.8%
₹380.7 lo₹877.2 hi
29.8% below 52W high — far from high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 4
1w13w26w
Week 4 — early Stage 2, building
How long this stock has been in Stage 2. The sweet spot is typically 13–26 weeks — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
15.3%
200 DMA: ₹534.2 · sloping down
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.26x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
MA20 trending up · +4.9% vs MA50 +10.6%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↓ Peaking
Stage 2%
48.9%
20d Δ
-1.5pp
1M return
+3.2%
3M return
+8.9%
Sector Stage-2 % · last 20 days
This stock ranks #73 of 84 Stage 2 stocks in Health Care by RS. Lagging sector peers.
Industry
Labs & Life Sciences Services
↑ Building
Stage 2%
33.3%
20d Δ
+16.7pp
1M return
+15.9%
3M return
+22.6%
Industry Stage-2 % · last 20 days
Ranks #2 of 2 Stage 2 stocks in this industry. Top tier.
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-30 → 2026-08-24
S2 21w
S2 40w
S2 16w
S4 14w
2023-05-302026-08-24
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 2w → S2 21w → S3 7w → S4 6w → S1 8w → S2 6w → S1 3w → S2 40w → S3 1w → S2 11w → S3 7w → S2 16w → S3 10w → S4 14w → S1 12w → S2 4w current
Total tracked: 168 weeks across 16 stage runs.
1M
+8.0%
3M
+34.1%
6M
+24.2%
YTD
-3.1%
1Y
-6.6%
Scan Membership
Prop Scan
Latest: 2026-08-24
Breakout Watch
Latest: 2026-07-29
21 appearances in last 60 days. First seen: 2024-04-04.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-24S2
Wk 4 · Vol x
2026-08-21S2
Wk 4 · Vol x
2026-08-20S2
Wk 4 · Vol x
2026-08-19S2
Wk 4 · Vol x
2026-08-18S2
Wk 3 · Vol x
2026-08-17S2
Wk 3 · Vol x
2026-08-14S2
Wk 3 · Vol x
2026-08-13S2
Wk 3 · Vol x
2026-08-12S2
Wk 3 · Vol x
2026-08-11S2
Wk 2 · Vol x
2026-08-10S2
Wk 2 · Vol x
2026-08-07S2
Wk 2 · Vol x
Sector Peers — Stage 2All →
MARKSANS
wk 14 · -2.7% from hi
9.8
ALIVUS
wk 20 · -2.3% from hi
9.4
MOREPENLAB
wk 10 · -1.3% from hi
9.2
NEULANDLAB
wk 13 · -3.2% from hi
9.0
ANTHEM
wk 14 · -1.6% from hi
8.9
Moving averages & range
50 DMA
₹591.8
200 DMA
₹534.2
52W High
₹877.2
52W Low
₹380.7
5D Low
₹615.9
Resistance levels (recent highs)
20d High
₹656.8
60d High
₹656.8
120d High
₹656.8
250d High
₹877.2
Next resistance
+6.6%
to 20d High

All analytics based on EOD data. Data as of 2026-08-24. Past data patterns are not indicative of future results. This page is a data analytics tool only.